Alternative Chemotherapeutic Agents: Nitrosoureas, Cisplatin, Irinotecan

Neurosurgery Clinics of North America

Volumn 23, Issue 2, 2012, Pages 297-306

  Carrillo, Jose A ^a   Munoz, Claudia A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BCNU; CCNU; Chemotherapy; Cisplatin; Glioblastoma; Glioma; Irinotecan; Nitrosoureas

Indexed keywords

ANTICONVULSIVE AGENT; BEVACIZUMAB; CARMUSTINE; CISPLATIN; CYTOCHROME P450; ENZASTAURIN; ETOPOSIDE; FOTEMUSTINE; IRINOTECAN; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PLACEBO; TEMOZOLOMIDE;

ADJUVANT THERAPY; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTICHOLINERGIC SYNDROME; BONE MARROW SUPPRESSION; BRAIN INFECTION; BRAIN SURGERY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; DIARRHEA; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; DRUG UTILIZATION; FATIGUE; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HEARING LOSS; HUMAN; INTRACRANIAL HYPERTENSION; LACTATE DEHYDROGENASE BLOOD LEVEL; LETHARGY; LEUKOPENIA; LUNG DISEASE; LUNG FIBROSIS; LYMPHOCYTOPENIA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PERCEPTION DEAFNESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; TINNITUS; TOXIC HEPATITIS; TREATMENT OUTCOME; VEIN DISEASE; VEIN SCLEROSIS; WOUND HEALING IMPAIRMENT;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CAMPTOTHECIN; CISPLATIN; GLIOMA; HUMANS; NITROSOUREA COMPOUNDS;

EID: 84858605866     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2012.01.005     Document Type: Review

References (36)

1. DeAngelis L., Burger P., Green S., et al. Malignant glioma: who benefits from adjuvant therapy?. Ann Neurol 1998, 44:691-695.
2. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials: Glioma Meta-Analysis Trialists (GMT) group. Lancet 2002, 359:1011-1018.
3. Stupp R., Mason W., van den Bent M., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
4. Bonnem E., Litterst C., Smith F. Platinum concentrations in human glioblastoma multiforme following the use of cisplatin. Cancer Treat Rep 1982, 66:1661-1663.
5. Yung W.K., Janus T., Maor M., et al. Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas. J Neuro Oncol 1992, 12:131-135.
6. Lassen U., Kristjansen P., Wagner A., et al. Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study. J Neuro Oncol 1999, 43:161-166.
7. Macdonald D., Cascino T., Schold S., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8:1277-1280.
8. Silvani A., Gaviani P., Lamperti E., et al. Cisplatinum and BCNU chemotherapy in primary glioblastoma patients. J Neuro Oncol 2009, 94:57-62.
9. Shinoda J., Sakai N., Hara A., et al. Clinical trial of external beam-radiotherapy combined with daily administration of low-dose cisplatin for supratentorial glioblastoma multiforme - a pilot study. J Neuro Oncol 1997, 35:73-80.
10. Marshall N.E., Ballman K.V., Michalak J.C., et al. Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients. J Neuro Oncol 2006, 77:315-320.
11. Friedman H., Petros W., Friedman A., et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999, 17:1516-1525.
12. Loghin M., Prados M., Wen P., et al. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a North American brain tumor consortium study. Clin Cancer Res 2007, 13:7133-7138.
13. Brandes A., Tosoni A., Basso U., et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 2004, 22:4779-4786.
14. Chamberlain M.C. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neuro Oncol 2002, 56:183-188.
15. Hare C., Elion G., Houghton P., et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 1997, 39:187-191.
16. Prados M., Lamborn K., Yung W.K., et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American brain tumor consortium study. J Neuro Oncol 2006, 8:189-193.
17. Batchelor T., Gilbert M., Supko J., et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. J Neuro Oncol 2004, 6:21-27.
18. Von Hoff D., Rothenberg M., Pilot C., et al. Phase II trial of irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer: overall results of FDA-reviewed pivotal US clinical trials. Proc Am Soc Clin Oncol 1997, 16:228a.
19. Quinn J., Jiang S., Reardon D., et al. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. J Neuro Oncol 2009, 95:393-400.
20. Vrendenburgh J., Desjardins A., Herndon J., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25:4722-4729.
21. Friedman H., Prados M., Wen P., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733-4740.
22. Wolff J., Berrak S., Webb S.E., et al. Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients. J Neuro Oncol 2008, 88:57-63.
23. Rosenblum M., Reynolds A., Smith K., et al. Chloroethyl-cyclohexyl-nitrosourea (CCNU) in the treatment of malignant brain tumors. J Neurosurg 1973, 39:306-314.
24. Reagan T., Bisel H., Childs D., et al. Controlled study of CCNU and radiation therapy in malignant astrocytomas. J Neurosurg 1976, 44:186-190.
25. Herrlinger U., Rieger J., Koch D., et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UCT-03. J Clin Oncol 2006, 24:4412-4417.
26. Wick W., Puduvalli V.K., Chamberlain M.C., et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010, 28:1168-1174.
27. Ballman K.V., Buckner J.C., Brown P.D., et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. J Neuro Oncol 2007, 9:29-38.
28. Hegi M., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
29. Vinjamuri M., Adumala R., Altaha R., et al. Comparative analysis of temozolomide (TMZ) versus 1,3-bis(2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients. J Neuro Oncol 2009, 91:221-225.
30. Reithmeier T., Graf E., Piroth T., et al. BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. BMC Cancer 2010, 10:30-38.
31. Brandes A., Tosoni A., Franceschi E., et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol 2009, 64:769-775.
32. Westphal M., Hilt D., Bortey E., et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. J Neuro Oncol 2003, 5:79-88.
33. Westphal M., Ram Z., Riddle V., et al. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir 2006, 148:269-275.
34. McGirt M., Than K., Weingart J., et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009, 110:583-588.
35. Scoccianti S., Detti B., Sardaro A., et al. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs 2008, 19:613-620.
36. Fabrini M., Silvano G., Lolli I., et al. A multi-institutional phase II study on second-line fotemustine chemotherapy in recurrent glioblastoma. J Neuro Oncol 2009, 92:79-86.